Renika McLeod-Labissiere, MD
Family Medicine · Prospect, CTNPI 1578648606
Payments from drug & device makers
Across 93 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$244
- GSK$173
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$147
- Pfizer$135
- Sanofi-aventis U.S. LLC$128
- Takeda Pharmaceuticals U.S.A., Inc.$118
- plus $622 from 11 others
What the payments were for
- Food & beverage$1,562100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 11 | $244 |
| GSK | 10 | $173 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $147 |
| Pfizer | 9 | $135 |
| Sanofi-aventis U.S. LLC | 7 | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $118 |
| AstraZeneca | 8 | $109 |
| Novo Nordisk | 5 | $103 |
| Lilly USA, LLC | 6 | $90 |
| AbbVie(2 entities) | 6 | $87 |
| Merck | 4 | $64 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| Aytu Biopharma, Inc. | 2 | $30 |
| Johnson & Johnson | 2 | $25 |
| Astellas Pharma US Inc | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Amgen | 1 | $20 |
How this compares
$1,566 in reported general payments places this provider in the 75th percentile of 588 family medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 35 | $50,802 |
| JardianceEmpagliflozin | 37 | $33,158 |
| EliquisApixaban | 34 | $27,482 |
| JanuviaSitagliptin Phosphate | 15 | $23,637 |
| MounjaroTirzepatide | 12 | $12,472 |
| XareltoRivaroxaban | 13 | $9,447 |
| Atorvastatin Calcium | 273 | $1,757 |
| Levothyroxine Sodium | 149 | $1,513 |
| SynthroidLevothyroxine Sodium | 13 | $1,439 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $1,058 |
| Rosuvastatin Calcium | 120 | $1,050 |
| Losartan Potassium | 80 | $554 |
| Omeprazole | 70 | $480 |
| Oxybutynin Chloride ErOxybutynin Chloride | 27 | $451 |
| Metformin Hcl | 94 | $433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $103 | $50,80235 claims |
| Boehringer IngelheimJardiance | $244 | $33,15837 claims |
| PfizerEliquis | $135 | $27,48234 claims |
| MerckJanuvia | $64 | $23,63715 claims |
| Lilly USA, LLCMounjaro | $90 | $12,47212 claims |
| Johnson & JohnsonXarelto | $25 | $9,44713 claims |
| AbbVieSynthroid | $87 | $1,43913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 588 family medicine providers in Connecticut.
Other family medicine in Prospect
- Debra GramlichStamford$292K
- Hadrian HolderNew Haven$213K
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Raja FattalehPutnam$53K
- Nicholas TzikasNew Haven$46K
- Andrew SelingerBristol$31K
- Helar CamposNew London$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.